SBC Medical fair value target raised to $9.25
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
SBC Medical Group Holdings' fair value price target was raised to $9.25 from $8.25 on updated financial assumptions, including higher revenue growth and future P/E levels. Third-quarter 2026 results showed significant revenue and EBITDA growth, helped by new clinic openings and AI alliances with NeuroBrain Dynamics and AtomicSoftware.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.